CSPC Pharmaceutical Group Limited, commonly known as CSPC Pharmaceutical Group, is a leading pharmaceutical company headquartered in Shijiazhuang, Hebei, China, with a corporate presence also noted in Hong Kong. Founded in 1992, with its predecessor listed on the Hong Kong Stock Exchange in 1994, it operates as a publicly held company under the ticker HKEX: 1093. As of late 2025 and early 2026, CSPC employs approximately 19,700 to 21,400 individuals, reported a trailing 12-month revenue of $3.62 billion (as of December 31, 2025), and holds a market capitalization of around $11.6 billion.
The company is engaged in the research, development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products. Its operations are primarily divided into two segments: finished drugs and bulk drugs. The finished drug portfolio includes innovative and generic medicines across therapeutic areas such as nervous system diseases, oncology, anti-infectives, and cardiovascular disease, featuring products like NBP for stroke, Duomeisu for various cancers, and Debixin for ulcers. Its bulk drug segment manufactures active pharmaceutical ingredients (APIs) for vitamin C, antibiotics (e.g., penicillin G), and caffeine. CSPC also provides functional food products and healthcare services.
CSPC Pharmaceutical Group exhibits an active, two-way patent litigation posture. The company has been involved in two tracked cases, appearing once as a plaintiff and once as a defendant. Its plaintiff case, initiated on January 16, 2025, is against Ipsen Biopharm Ltd. before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office. Conversely, CSPC Pharmaceutical Group Limited is a defendant in a case filed on April 15, 2024, in the U.S. District Court for the District of New Jersey, brought by IPSEN BIOPHARMACEUTICALS, INC. et al.
The company's engagement as both a plaintiff and defendant against Ipsen suggests potential disputes over specific pharmaceutical intellectual property. This indicates CSPC is an operating company actively protecting and defending its patents and products rather than a non-practicing entity. In recent external context, CSPC Pharmaceutical Group has also entered into a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates for weight management and other indications.